Home biologics
 

Keywords :   


Tag: biologics

Aptimmune Biologics selected by The Yield Lab to participate in Ag Technology Accelerator Program

2016-11-17 20:40:54| National Hog Farmer

Aptimmune Biologics was selected by The Yield Lab, a St. Louis-based agriculture technology business accelerator and investor, to participate in a nine-month program designed to support emerging ag tech companies. Aptimmune Biologics was chosen from among 120 applicants to participate in the program for 2016 and represents The Yield Labs first animal health investment. read more

Tags: technology program selected participate

 

Green Biologics & HOC Industries Partner to Package & Distribute Renewable Consumer Products

2016-11-02 16:04:00| Coatings World Breaking News

Tags: products partner green package

 
 

Green Biologics Unveils High Purity, Bio-Based Product Brands: BioPure & GreenInside

2016-10-12 22:00:00| Coatings World Breaking News

Tags: high product green brands

 

Green Biologics & Caldic Partner to Bring Renewable Chemicals to EU Market

2016-10-04 07:00:00| Coatings World Breaking News

Tags: to market partner green

 

FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Mercks KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2016-09-07 12:45:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Merck Has Also Submitted a Marketing Authorization Application to the European Medicines Agency for KEYTRUDA in the Same Patient Population Submissions Based on Data from KEYNOTE-024 Trial Showing Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Express High Levels of PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with a PDUFA, or target action, date of Dec. 24, 2016. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: advanced review application license

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »